CD8A and cancer: In animal models, a successful anti-cancer immune response does not simply rely on MHC-I–restricted neoantigens to drive tumor antigen-specific CD8 T cell responses; the presentation of neoantigens on MHC class II (MHC-II) molecules to CD4 T cells within tumors also plays an essential role [4, 53, 54].